Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.

3.3 Longitudinal analysis Analyses of the mITT population showed a trend towards longer QFS in favor of the sLV5FU2 group among the five targeted dimensions, namely physical functioning (HR = 0.64 [90% CI 0.40‐1.03]), emotional functioning (HR = 0.71 [90% CI 0.44‐1.16]), fatigue (HR = 0.79 [90% CI 0.50‐1.26]), pain (HR = 0.62 [90% CI 0.38‐1.01]) and appetite loss (HR = 0.70 [90% CI 0.44‐1.13]), with HRs < 1 (Figure 3 ).

also in 53,322 other papers